Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?

Publication date: Available online 22 September 2017 Source:Best Practice & Research Clinical Haematology Author(s): Richard M. Stone For 4 decades, new agents had not been approved for use in treating acute myeloid leukemia (AML). The long dry spell was broken in 2017, however, with the approval or recommendation for approval of several agents: midostaurin for addition to chemotherapy in mutant FLT3 patients undergoing intensive chemotherapy, enasidenib in advanced mutant IDH2 patients, CPX-351 in secondary AML patients, and gemtuzumab ozogamicin in conjunction with standard chemotherapy in AML. This review surveys the use of tyrosine kinase inhibitors to treat patients with mutant FLT3 AML, mutant KIT AML, as well as IDH inhibitors and explores some questions regarding their integration into the treatment armamentarium for AML.
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research